LDL cholesterol (LDL-C)
Not yet reviewed by a clinician. This page was drafted with AI assistance from the studies cited below and checked against them by a separate automated review. It is general information, not medical advice.
Last updated November 16, 2026
Kyruno
- Also called
- LDL-C, LDL, Low-density lipoprotein cholesterol, Bad cholesterol
- Body system
- Heart and blood vessels
- Unit
- mg/dL
Evidence grades: A = consistent results from multiple randomized controlled trials or meta-analyses. B = at least one randomized controlled trial, or consistent large observational studies. C = observational or mechanistic evidence only. D = preliminary or conflicting evidence.
What it is
LDL cholesterol (LDL-C) is the cholesterol carried inside low-density lipoprotein (LDL) particles, one of the cholesterol-carrying particles linked to plaque in the arteries. It is the number lipid guidelines have long used to grade cholesterol and to set treatment goals [1][2].
The European guideline keeps goals for LDL cholesterol, adds secondary goals for non-HDL cholesterol and ApoB, and prefers ApoB when refining an estimate of risk, because ApoB counts all of the cholesterol-carrying particles that drive plaque [2].
On a routine lipid panel, LDL cholesterol is usually calculated from the other results rather than measured directly [3].
Typical ranges
US cut-offs from the National Cholesterol Education Program grade LDL cholesterol in adults as follows [1].
| LDL cholesterol (mg/dL) | Classification (ATP III, 2001) [1] |
|---|---|
| Below 100 | Optimal |
| 100 to 129 | Near or above optimal |
| 130 to 159 | Borderline high |
| 160 to 189 | High |
| 190 and above | Very high |
Guidelines set LDL cholesterol goals by a person's overall cardiovascular risk, not by one cut-off for everyone. ATP III did this in 2001, with goals below 100, 130 or 160 mg/dL depending on risk [1]. The 2019 European goals are lower.
| Source | Risk group | LDL cholesterol goal |
|---|---|---|
| ESC/EAS 2019 [2] | Very high | Below 55 mg/dL (1.4 mmol/L) and at least 50% lower than baseline |
| ESC/EAS 2019 [2] | High | Below 70 mg/dL (1.8 mmol/L) and at least 50% lower than baseline |
| ESC/EAS 2019 [2] | Moderate | Below 100 mg/dL (2.6 mmol/L) |
| ESC/EAS 2019 [2] | Low | Below 116 mg/dL (3.0 mmol/L) |
As summarized in Endotext, the 2018 US guideline puts less weight on fixed goals and more on lowering LDL cholesterol by a set percentage. For people at very high risk who already have cardiovascular disease, it uses 70 mg/dL as the level above which adding another cholesterol-lowering medicine to a statin is considered, and it counts LDL cholesterol that stays above 160 mg/dL as a risk-enhancing factor [3]. Which risk group applies to a person is a clinical judgment.
What raises it
Saturated fat in the diet
In a WHO meta-regression of controlled diet studies (69 studies, 165 diets reporting LDL cholesterol), LDL cholesterol was higher when saturated fat took the place of polyunsaturated fat, monounsaturated fat or carbohydrate [4]. Diets high in saturated or trans fat, and ketogenic diets, are also listed among causes of raised LDL cholesterol [3].
Inherited cholesterol disorders
Familial hypercholesterolemia is an inherited cause of high LDL cholesterol. Endotext puts mutations in the LDL receptor gene at about 1 in 250 people and in the ApoB gene at about 1 in 1,000. When LDL cholesterol is above 190 mg/dL, it advises checking family members' lipids and, where possible, genetic testing [3].
Other medical conditions
Conditions listed as raising LDL cholesterol include hypothyroidism, nephrotic syndrome, obstructive liver disease, Cushing's syndrome, growth hormone deficiency, anorexia nervosa and pregnancy [3].
Some medicines
Medicines listed as raising LDL cholesterol include glucocorticoids, cyclosporine and tacrolimus, amiodarone, anabolic steroids, androgen deprivation therapy, retinoids, thiazide and loop diuretics, some progestins, protease inhibitors and SGLT2 inhibitors, among others [3]. Never stop or change a prescribed medicine because of a lab result; talk to the prescriber.
What lowers it
Replacing saturated fat with unsaturated fat
In the WHO meta-regression, each 1% of daily calories moved from saturated to polyunsaturated fat lowered LDL cholesterol by 0.055 mmol/L (about 2.1 mg/dL). Moving it to monounsaturated fat lowered LDL cholesterol by 0.042 mmol/L (about 1.6 mg/dL), and to carbohydrate by 0.033 mmol/L (about 1.3 mg/dL) [4].
Psyllium fiber
A meta-analysis of 28 randomized trials (1,924 people with or without high cholesterol, median about 10 g of psyllium a day) found LDL cholesterol fell by 0.33 mmol/L (about 13 mg/dL; 95% CI 0.27 to 0.38 mmol/L) compared with control. The authors rated this moderate-quality evidence because results varied between trials [5].
Oat beta-glucan
Across 56 randomized trials that reported LDL cholesterol (3,745 people, median 3.5 g of oat beta-glucan a day for a median of 6 weeks), LDL cholesterol fell by 0.19 mmol/L on average (about 7 mg/dL, or about 4%). Results varied widely between trials and this could not be explained, so the authors advise caution in reading the result. Many trials also had unclear or high risk of bias [6].
Plant sterols and stanols
A meta-analysis of 124 randomized studies, mostly of foods with added plant sterols or stanols, found the LDL-lowering effect grew with the dose: about 6% at an average 0.6 g a day, about 8% at 2.1 g and about 12% at 3.3 g. Sterols and stanols worked about equally up to roughly 3 g a day. Two of the three authors worked for a company that sold foods with added plant sterols [7].
Cholesterol-lowering medicines
Endotext notes that diet is the first step but usually does not reach the goal on its own, and describes medicines that lower LDL cholesterol [3]. Whether a medicine is needed, and which, is a decision for a clinician.
Testing
- Fasting is usually not needed. A joint European consensus statement found that, on average, LDL cholesterol was at most about 0.2 mmol/L (about 8 mg/dL) lower after ordinary meals than when fasting, a change it judged not clinically significant. It suggests considering a fasting sample when non-fasting triglycerides are above 440 mg/dL (5 mmol/L) [8].
- High triglycerides weaken the calculation. A routine lipid panel reports a calculated LDL cholesterol. When fasting triglycerides are high (above roughly 200 to 400 mg/dL) it cannot be calculated accurately, and a directly measured LDL cholesterol may help [3].
- Pregnancy is listed among the conditions that raise LDL cholesterol [3].
- Units. To convert LDL cholesterol from mmol/L to mg/dL, multiply by 38.6 [8]. The European goals of 55, 70, 100 and 116 mg/dL correspond to 1.4, 1.8, 2.6 and 3.0 mmol/L [2].
- LDL cholesterol is read with the rest of the lipid panel and a person's overall risk, not on its own [1][2].
Notes
Talk to a clinician about LDL cholesterol of 190 mg/dL or higher, a result above the goal for your risk group, or a family history of very high cholesterol or early heart disease [1][3]. Talk to the prescriber before changing any prescribed medicine. Whether and when to repeat the test is a clinician's call.
This page is general information, not medical advice. Evidence grades use Kyruno's A to D scale.
This page is general information, not medical advice. Talk to a qualified clinician about your own results and before changing supplements or medication.
References
- National Cholesterol Education Program. High Blood Cholesterol: ATP III Guidelines At-A-Glance Quick Desk Reference. National Heart, Lung, and Blood Institute (NIH Publication No. 01-3305) (2001)
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal (2020) · PMID: 31504418
- Feingold KR. Approach to the Patient with Dyslipidemia. Endotext (updated June 25, 2025) (2025)
- Mensink RP. Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis. World Health Organization (ISBN 978 92 4 156534 9) (2016)
- Jovanovski E, Yashpal S, Komishon A, Zurbau A, Blanco Mejia S, Ho HVT, et al.. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition (2018) · PMID: 30239559
- Ho HVT, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, et al.. The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. British Journal of Nutrition (2016) · PMID: 27724985
- Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. British Journal of Nutrition (2014) · PMID: 24780090
- Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al.. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points. A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal (2016)